Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 35.385 USD -0.58%
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one SUPN stock under the Base Case scenario is 38.643 USD. Compared to the current market price of 35.385 USD, Supernus Pharmaceuticals Inc is Undervalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SUPN Relative Value
Base Case
38.643 USD
Undervaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
11
vs Industry
41
Median 3Y
2.8
Median 5Y
2.8
Industry
2.5
Forward
3
vs History
31
vs Industry
0
Median 3Y
34.5
Median 5Y
23.4
Industry
21.8
Forward
12.2
vs History
57
vs Industry
25
Median 3Y
14.3
Median 5Y
12.5
Industry
16.1
vs History
28
vs Industry
21
Median 3Y
8.3
Median 5Y
9
Industry
23.8
vs History
38
vs Industry
43
Median 3Y
1.9
Median 5Y
1.9
Industry
2.1
vs History
66
vs Industry
46
Median 3Y
2.6
Median 5Y
2.6
Industry
2.7
Forward
2.4
vs History
65
vs Industry
64
Median 3Y
3
Median 5Y
3
Industry
5.2
vs History
49
vs Industry
19
Median 3Y
14.2
Median 5Y
11.3
Industry
13.5
Forward
12.7
vs History
38
vs Industry
4
Median 3Y
40.7
Median 5Y
16
Industry
16.8
Forward
9
vs History
73
vs Industry
29
Median 3Y
13.6
Median 5Y
12
Industry
15.2
vs History
74
vs Industry
25
Median 3Y
13.8
Median 5Y
12
Industry
19.3
vs History
4
vs Industry
48
Median 3Y
1.4
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

SUPN Competitors Multiples
Supernus Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
2B USD 3 32.7 11 26.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.1B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
348B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
150.1B USD 2.5 35.4 10.5 15.9
P/E Multiple
Earnings Growth P/E to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average P/E: 32.4
32.7
9 887%
0
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average EV/EBITDA: 414.7
11
53%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average EV/EBIT: 1 812.7
26.4
923%
0
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Discover More
Back to Top